Oncology Drug Pathway Analyzer Linkedin V1.0
- 1. Oncology Drug Pathway Analyzer™ BioSeeker Group AB May, 2012
- 2. You Use this Analyzer Tool to: Map the competition and find suitable benchmarking drugs based on specific pathways and drug properties Uncover potential indication expansion areas for your drug portfolio Reveal repositioning opportunities for your older, shelved drugs Evaluate the progression and success of targeting certain pathways for the treatment of cancer Investigate drugs which affect crosstalk between key pathways Investigate different combination therapy options available to you in various cancer types. Use this tool to look for the most- efficient ways to combine your drug with other targeted agents. Find possible adjuvant therapy settings with other drugs
- 3. How you get instant, interactive pathway modeling on almost 3,000 cancer drugs! Go from very niched The Analyzer will pathways to broad process almost general pathways. The 3,000 drugs which together have more Analyzer includes than 6,200 hundreds of pathways Pathways developmental from BioCarta, KEGG Drugs projects in cancer and Netpath Oncology There are 87 Drug Pathway cancer indications Analyzer™ to cross-reference Indications The near 3,000 with drugs have close Targets to 700 molecular targets, linking them to several hundred pathways
- 4. Drugs Facts: Refine Pathway Modeling by: • Almost 3,000 (2,820) cancer drugs • Drug Name • More than 6,200 developmental • Drug Status projects • Compound Type • Company • Drug Development Partners Cancer Drug Development Ceased Suspended Preclinical Phase I Phase II Phase III Pre-registration Registered Marketed 0 200 400 600 800 1000
- 5. Targets Facts: Refine Pathway Modeling by: • Almost 700 (694) molecular • Target Name targets, which link the near 3,000 drugs • Molecular Function to several hundred pathways • Mechanism • They represent 90 different molecular • Target Localization functions • They are found in 41 different subcellular localizations Top 5 Molecular Functions Top 5 Target Localizations Transmembrane receptor protein Endoplasmic reticulum tyrosine kinase activity Catalytic activity Extracellular Protein serine/threonine kinase Nucleus activity G-protein coupled receptor Cytoplasm activity Receptor activity Plasma membrane 0 20 40 60 80 100 0 50 100 150 200 250 300
- 6. Cancer Indications Cancer Indications Acute Lymphocytic Leukemia Acute Myelogenous Leukemia Facts: Adrenal Cancer • There are 87 cancer indications to cross-reference with Basal Cell Cancer B-cell Lymphoma Refine Pathway Modeling by: Benign prostatic hyperplasia • Indication Top 5 Included Cancer Indications Biliary Cancer • Developmental Stage • Clinical Status Bladder Cancer Ovarian Cancer Bone Cancer Non-Small Cell Lung Cancer Brain Cancer Colorectal Cancer Breast Cancer Prostate Cancer Cancer (general) Breast Cancer Carcinoid 0 50 100 150 200 250 300 350 400 450 Carcinoid syndrome Cervical Cancer
- 7. Pathways Facts: • Go from very niched pathways to broad general pathways. The Analyzer includes hundreds of pathways from BioCarta, KEGG and Netpath Netpath (25) EGFR1 Signaling TGF-beta Receptor Signaling KEGG (205) Focal adhesion ErbB signaling Jak-STAT signaling MAPK signaling BioCarta (315) Erk1/Erk2 Mapk Signaling Ras Signaling EGF Signaling MAPKinase Signaling AKT Signaling p53 Signaling
- 8. Real Case Scenario (combination therapy): In the March 20, 2012 issue of the journal Cancer Cell, researchers at The University of Texas MD Anderson Cancer Center reveal that the mTOR molecular pathway stimulates the activity of the Gli1 protein in the development and progression of esophageal cancer. Hitherto it is known that the Hedgehog pathway is the established pathway for activating Gli1. In experiments the researchers then went on to show that a combination of the mTOR inhibitor everolimus (Afinitor) and the Hedgehog inhibitor vismodegib (Erivedge) steeply reduced the tumor burden in a mouse model of esophageal adenocarcinoma. The Analyzer would in seconds: Accesses how many and which drug are available for potential drug combination therapies in affecting both the Hedgehog- and the mTOR pathway Overlay the mTOR pathway with the Hedgehog pathway and then report which drugs affect both pathways and how Allow you to further refine the above two results (using up to twelve different filter settings), for an example by either limiting the findings to esophageal cancer and/or only listing approved drugs like everolimus (Afinitor) and vismodegib (Erivedge)
- 9. The Oncology Drug Pathway Analyzer Comes in Two Versions
- 10. Drug Profile Reports (Premium) • Dynamic Report Generator – Single Drug – Multiple Drugs Matching Your Criteria • Each Profile Reports on Up to 15 Information Classifications on a Drug: Name & Synonyms Business & Market Phase III Company & Partners Target Data Phase II Drug Description Mechanism Phase I Compound Data Pathway Preclinical Patent Data Developmental Projects Licensing • Estimated 6,200 page report to print data for all drugs included
- 11. Start Using the Analyzer Today! 1. It's the only tool of its kind 2. It sits right at your desktop, not in department above you or across the ocean 3. Once you get it you have it! No subscription 4. So, bring out the power in your pipeline and start to quickly analyze the impact of emerging pathway data in cancer by getting your own version of the Oncology Drug Pathway Analyzer. 5. It comes in two versions, Standard and Premium. The additional great feature of the Premium version is that it also gives you instant access to almost 3,000 up to date and extensive drug developmental profiles (at the low price of around 1 EUR/profile). Price Price License Type (Standard) (Premium) Single 6,900 EUR 9,900 EUR Global 13,800 19,800
- 12. Thank You